全网公布的阿福他酶α2025年最新价格

Asfotase alfa is a key drug in the treatment of hypophosphatasia. The original drug price of 18mg/0.45mL/box is about US$13,205. There are currently no generic drugs on the market. This drug needs to strictly follow the medication guidelines, including individualized dose adjustment and injection regimen selection, and the contraindicated groups should be clearly defined to avoid adverse reactions.

The latest price of aftase alpha in 2025 announced on the entire network

The original drug Strensiq is produced by Ruisong Pharmaceuticals (now a subsidiary of AstraZeneca) in the United States.

Original drug price

The price of aftase α 18mg/0.45mL/box in 2025 is approximately US$13,205. This drug is a rare disease drug, and its high price is mainly affected by research and development costs, production complexity and market demand.

Current status of the generic drug market

Currently, no generic drug of aftase alpha has been approved for marketing globally. Due to strict restrictions on patent protection and biosimilar drug approval, it will be difficult to enter the market in the short term.

The high cost of aftase alpha limits its accessibility, and patients expect future medical insurance policies or generic drugs to reduce the treatment burden.

Afotalase α Medication Guide

Afotalase α needs to be used under the supervision of a professional medical team. The dosage regimen should be adjusted according to the patient’s age and severity of the disease. Correct medication is crucial to improving the prognosis of patients with hypophosphatasia.

Recommendations before treatment

Treatment should be initiated in an institution with complete medical monitoring conditions and guided by a physician who is familiar with HPP treatment. Before treatment, the patient's skeletal development, respiratory function and biochemical indicators need to be assessed to formulate an individualized plan.

Dosage of fetal/infancy-onset HPP

The recommended starting dose is 6 mg/kg subcutaneous injection per week, with options of 2 mg/kg 3 times per week or 1 mg/kg 6 times per week. If the effect is insufficient, it can be increased to 9mg/kg per week (3mg/kg 3 times per week).

Adolescent-onset HPP dose

The dose for adolescent patients is the same as in infancy, with 6 mg/kg divided injections per week. It should be noted that frequent injections may cause local reactions, and the frequency of administration should be adjusted if necessary.

Reasonable adjustment of the dose of aftase α can maximize the therapeutic effect while reducing the risk of adverse reactions.

Contraindicated groups for aftase α

Although aftase α has significant efficacy, some patient groups need to use it with caution or it is prohibited. Clearly identifying contraindication groups can avoid serious adverse events.

Patients allergic to active ingredients or excipients

It is contraindicated in patients who have experienced severe allergic reactions (such as anaphylactic shock, angioedema) after using aftase alfa in the past. Detailed inquiries about allergy history are required before taking medication.

Patients with severe hepatic insufficiency

The metabolism of aftase alpha may be affected by liver function, and patients with severe liver disease should use it with caution. Liver function indicators should be monitored during treatment and the dose should be adjusted if necessary.

Patients with uncontrolled infection

For patients in the acute infection stage, medication should be postponed until the infection is controlled before re-evaluation. Immunosuppressive status may affect drug metabolism and efficacy.

Patients should monitor the treatment response during medication and promptly notify the doctor if adverse reactions occur.